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Key messages
What is already known about this subject?
 ► the goal of managing axial spondyloarthritis (axSpa) 
is to improve and maintain patients’ health-related 
quality of life (HrQol), mainly through targeting to-
wards low disease activity.
 ► trajectories with respect to disease activity have 
been identified in patients with early axSpa.
What does this study add?
 ► We identified five latent groups displaying similar 
trajectories of HrQol and disease activity in patients 
with established axSpa.
 ► the profiles revealed that both individual-related 
and disease-related features define the impact of 
axSpa.
How might this impact on clinical practice?
 ► the profiles may provide clinicians insight into the 
differences among patients and help in the manage-
ment of axSpa.
AbstrAct
Objective the goal of managing axial spondyloarthritis 
(axSpa) is to improve and maintain patients’ health-
related quality of life (HrQol), mainly through targeting 
towards low disease activity. Here, we aim to gain insight 
into the joint evolution of HrQol and disease activity by 
identifying and characterising latent subgroups of patients 
with longstanding disease displaying similar trajectories 
throughout 8  years of follow-up.
Methods Data from Outcome in ankylosing Spondylitis 
(aS) international Study (n=161) and groningen 
leeuwarden aS cohort (n=264) were used. Biennially, 
HrQol was assessed by aS Quality of life (aSQol) and 
disease activity by aS Disease activity Score—c reactive 
protein (aSDaS-crP). Bivariate trajectories of these 
outcomes were estimated by group-based trajectory 
modelling. next, trajectories were profiled by comparing 
the latent groups with respect to baseline factors using 
analysis of variance and χ² test.
Results Five bivariate trajectories were distinguished, in 
which aSQol and aSDaS-crP were tightly linked: (t1) low 
impact of disease; (t2) moderate impact; (t3) high impact 
with major improvement; (t4) high impact with some 
improvement; (t5) very high impact. Profiling revealed, for 
example, that (t1) was characterised by male gender and 
Human leucocyte antigen B27 positivity; (t3) by younger 
age, shorter symptom duration and biological intake and 
(t5) by the highest proportion of females.
Conclusions We identified five bivariate trajectories of 
HrQol and disease activity demonstrating a clear mutual 
relationship. the profiles revealed that both individual-
related and disease-related features define the type of 
disease course in respect to HrQol and disease activity 
in axSpa. this may provide clinicians insight into the 
differences among patients and help in the management 
of the disease.
InTROduCTIOn
The clinical presentation of axial spondy-
loarthritis (axSpA) is heterogeneous and can 
include inflammatory back pain, arthritis, 
dactylitis and enthesitis. Furthermore, 
extra-articular manifestations commonly 
occur.1 As a consequence, patients might 
experience pain, fatigue, impaired physical 
function and restricted participation in social 
roles.2 This results in reduced health-related 
quality of life (HRQoL) and lower life-satisfac-
tion when compared with the general popula-
tion.3 In addition, restrictions in work partic-
ipation add to the socioeconomic impact 
of the disease for society.4 5 In clinical prac-
tice, improving and maintaining patients’ 
HRQoL is the ultimate goal of management 
of axSpA.6 Optimisation of HRQoL can be 
achieved through management of disease 
activity by means of (pharmacological) 
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therapy, for which a treat-to-target strategy is increasingly 
advocated.6 7
While differences among individuals with axSpA exist 
with respect to the clinical presentation, the type and 
severity of disease characteristics within an individual may 
also change over time.8 9 Several studies tried to explain 
variability in HRQoL and disease activity in axSpA using 
classic regression analyses. Variability in HRQoL has been 
related to pain, stiffness and fatigue and also to personal 
contextual factors such as education, helplessness or 
comorbidities.7 10–12 Variability in disease activity has been 
related to age, Human Leucocyte Antigen B27 (HLAB-
27) positivity, smoking and pharmacological treatment 
among which NSAIDs and tumour necrosis factor α 
(TNFα)-inhibitors.13–16 However, none of these studies 
investigated the presence of possible heterogeneity (ie, 
subgroups) within their population that is not necessarily 
attributable to known covariates. To gain more insight 
into this heterogeneity, a change of perspective might be 
of interest. Instead of addressing and explaining the vari-
ability of axSpA outcomes by the usual variables-centred 
approaches (like regression models), it is possible to take 
the variability itself as a starting point to cluster patients 
according to their clinical presentation over time. 
Multiple, not directly observable subgroups of patients 
are likely to emerge, each constituting a different symp-
tomatic course of disease. These latent subgroups are 
represented by longitudinal trajectories, which capture 
interindividual differences in intraindividual changes 
of selected outcome(s). The heterogeneity of clinical 
presentation in axSpA warrants the application of such 
person-centred approach, mainly because substantial 
variability is expected in the (course of) impact of axSpA 
and effect of treatment. In addition, revealed subgroups 
can be described by means of patients’ characteristics 
resulting in risk-stratification that may more closely meet 
the demands of daily clinical practice.
To gain such understanding, Moltó et al evaluated in 
a French cohort of patients with early axSpA the pres-
ence of potential latent subgroups with respect to 
disease activity during a 3-year follow-up period.17 Five 
disease activity trajectories were observed: (1) persistent 
moderate disease activity; (2) persistent inactive disease; 
(3) changing disease activity; (4) persistent high disease 
activity; (5) persistent very high disease activity. Interest-
ingly, in their study, a relation between the disease activity 
trajectories and the level of HRQoL at baseline was estab-
lished. Both HRQoL and disease activity are factors that 
reflect the impact of the disease in a person. As manage-
ment of disease activity should also be mirrored in gains 
in HRQoL, it is important to understand their joint evolu-
tion, that is, how temporal patterns of codependencies of 
the two outcomes unfold. The role of treatment herein, 
which is highly effective in controlling disease activity, 
would be of additional clinical relevance.
In the present study, we aimed to explore the heteroge-
neity of the impact of axSpA by identifying and character-
ising latent subgroups of patients with similar trajectories 
of HRQoL and disease activity in two well-phenotyped 
cohorts of patients with longstanding disease, who were 
followed biennially up to 8 years.
PaTIenTs and MeTHOds
Patients
Data from two prospective, multicentre, longitudinal 
observational cohort studies, Outcome in Ankylosing 
Spondylitis (AS) International Study (OASIS) and 
Groningen Leeuwarden AS (GLAS) cohort, were used 
for the present study.18 19 OASIS started in 1996 and 
was conducted at several secondary and tertiary referral 
centres in the Netherlands, Belgium and France. At base-
line, 217 patients were included, all fulfilling the modi-
fied New York criteria (mNYC).20 In order to increase 
the sample size and create a database most related to 
reality with all types of disease activity and treatments, 
including anti-TNF-α treatment, which was not yet avail-
able at the start of OASIS, the sample was enriched with 
patients from the GLAS cohort. GLAS started in 2004 
and was conducted in the north of the Netherlands. 
From this cohort, 266 patients who started anti-TNF-α 
treatment because of active disease between 2004 and 
2012 were included. Patients fulfilled either the mNYC or 
the imaging arm of the Assessment in SpondyloArthritis 
International Society criteria for axSpA.20 21 Patients 
from both cohorts were followed, according to a fixed 
protocol at regular intervals and follow-up continued also 
in patients stopping/switching treatment. All patients 
provided written informed consent according to the 
Declaration of Helsinki.
Outcome variables
HRQoL was assessed at each visit by the AS Quality of Life 
(ASQoL) questionnaire.22 The ASQoL is a need-based 
HRQoL questionnaire consisting of 18 impairments and 
limitations typical for axSpA. Score ranges from 0 to 18, 
higher scores imply worse HRQoL. A threshold of 8 was 
used to define a patient acceptable symptom state.23
Disease activity was evaluated at each visit by several 
constructs that allowed to calculate the AS Disease 
Activity Score with C-Reactive Protein (ASDAS-CRP).24 
ASDAS-CRP cut-offs were used to describe disease activity 
states: ‘inactive disease’ (<1.3), ‘low disease activity’ (≥1.3 
and<2.1), ‘high disease activity’ (≥2.1 and≤3.5) and 
‘very high disease activity’ (>3.5). A change of ≥1.1 in 
ASDAS-CRP was defined as ‘clinically important improve-
ment’ and ≥2.0 as ‘major improvement’.25
The following baseline parameters were available to 
further characterise the latent subgroups: age, gender, 
smoking status (yes/no), body mass index, symptom 
duration, CRP-level, HLA-B27 (positive/negative), pres-
ence of (bridging) syndesmophytes (yes/no) on spinal 
radiographic imaging and start of anti-TNF-α treat-
ment (yes/no). Further, Bath AS Disease Activity Index 
(BASDAI),26 Bath AS Functional Index (BASFI)27 and 
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both patient and physician Global Disease Activity were 
assessed.
statistical analysis
The analyses proceeded in two phases: (1) model selec-
tion consisting of identification of the latent trajectory 
groups and their functional forms and (2) characterisa-
tion of the unveiled groups. Patients without any ASQoL 
measurement were excluded from the analyses.
To identify clinically distinct trajectory classes of 
HRQoL and disease activity, group-based multitrajectory 
modelling (GBTM) was used, which is a form of latent 
class analysis.28 29 A major distinction between the multi-
variate GBTM, compared with its univariate version, is 
that in the former each identified trajectory is a repre-
sentation of the temporal course of several outcomes 
jointly (herein specifically HRQoL and disease activity). 
Thus, the bivariate-trajectories in this study were esti-
mated simultaneously, not individually, one at a time. As 
a result, each identified latent class captured individual 
patterns of changes of HRQoL and disease activity and 
the dynamics of their temporal codependencies. With 
GBTM, no prior defined classes are presumed, and there-
fore, heterogeneity in a population that is not attributed 
to any known factor can be uncovered. Models with 
increasing numbers of classes were run (from 1 up to 7) 
to determine the number of latent classes (class-enumer-
ation) with SAS procedure PROC TRAJ.28 We resorted to 
the Fit-Criteria Assessment Plot (FCAP) R-code to assist 
the process of class-enumeration.29 FCAPs are graphical 
displays providing eight goodness-of-fit and model-ade-
quacy criteria (Bayesian Information Criterion, Akaike’s 
Information Criterion, likelihood of assignment, average 
posterior probability of assignment, mismatch between 
estimated and assigned group probabilities, SD of group 
membership probabilities, odds of correct classification, 
proportion of individuals estimated to be assigned to 
the smallest group). After settling the number of latent 
classes, the polynomial order of the trajectories deter-
mining their final shape was selected, based on statis-
tical significance (see online supplementary material 
for a detailed description of the model fitting proce-
dure). GBTM estimates each participant’s probabilities 
for trajectories’ membership posthoc. A patient is then 
classified into the latent class for which (s)he shows the 
highest posterior probability of assignment.
Subsequent to model-selection, extracted HRQoL-dis-
ease activity trajectories were compared with respect to 
several baseline demographic and clinical variables with 
analysis of variance (posthoc Bonferroni correction) and 
χ² test, where appropriate.
Intermittent missingness (ie, a single variable or an 
entire visit missing, followed by complete assessment) was 
assumed to be missing at random. Loss to follow-up, that 
is, non-random attrition occurred. To test for differential 
drop-out, we computed for all classes the proportion of 
individuals with two or more missing values in the final 
and immediate preceding time points. Their frequencies 
were then compared.
Analyses were performed using SAS V.9.4, SPSS V.21 
and R V.3.2.0. The significance level was set at 0.05.
ResulTs
From the 217 patients included in the OASIS cohort, we 
removed the first 4 years of follow-up, because the ASQoL 
measurement was not available at that time. One patient 
was excluded from all (previous and current) analyses 
from OASIS, because of inconsistencies in the data. 
Another 56 patients had no ASQoL measurements after 
year 4. In total, 161 (74%) of the patients from the OASIS 
cohort were included in the current study. These patients 
did not differ in baseline characteristics from the entire 
cohort. From the GLAS cohort, 2 patients were excluded 
because of unavailability of ASQoL measurements, and 
264 patients (99%) were included.
Ultimately, the analyses were conducted on a multico-
hort of 425 unique patients, who were followed bienni-
ally up to four time points after inclusion in the present 
study. Sometimes, individual patients missed measure-
ment points. At time point 0, data from 411 patients were 
available, after 2 years from 363 patients, after 4 years 
from 290 patients, after 6 years from 238 patients, and 
after 8 years from 158 patients.
Identifying latent HRQol-disease activity trajectory groups
Baseline characteristics of the overall patient population 
and separately for each cohort are provided in table 1. 
Patients included in OASIS were characterised by older 
age, longer symptom duration and higher proportion of 
(bridging) syndesmophytes in comparison to the GLAS 
population. Due to the inclusion criteria of GLAS, these 
patients were characterised by higher CRP, BASDAI and 
proportion prescribed TNFα-inhibitors.
According to model-adequacy criteria, the five-class 
solution provided the best fit to the data (online supple-
mentary figure 1 and online supplementary table 1). The 
spaghetti plots (figure 1) display individual-specific lines 
within each of these five latent classes. Each extracted 
latent class is assigned one colour and represented by two 
developmental trajectories: an ASQoL (HRQoL)-CRP 
and an ASDAS-CRP (disease activity) trajectory. There-
fore, the developmental paths displayed convey individual 
temporal progressions of HRQoL and disease activity 
and their coevolution. For instance, subjects assigned to 
class 1 (green) showed a gradual improvement in disease 
activity with concurrently a good and stable temporal 
unfolding of HRQoL. Similarly, those patients assigned 
to trajectory 3 (black) showed a major decrease in disease 
activity and had at the same time a substantial improve-
ment of HRQoL, already after baseline. By analogy, the 
same interpretation of temporal covariation between 
disease activity and HRQoL extends to the other develop-
mental classes. Since the trajectories illustrate concomi-
tant patterns of change and/or stability of HRQoL and 
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Table 1 Baseline characteristics of the patients
Characteristics
OASIS
(n=161)*
GLAS
(n=264)* P values
Overall
(n=425)*
Age (years) 49.1 (11.7) 42.7 (11.9) <0.001 45.2 (12.2)
Male sex 112 (69.6%) 179 (67.8%) 0.704 291 (68.5%)
Smoking—yes 41/116 (35.3%) 88/229 (38.4%) 0.576 129/345 (37.4%)
BMI 26.5 (4.9) 26.6 (4.3) 0.817 26.5 (4.5)
Symptom duration 26.0 (11.5) 17.2 (11.3) <0.001 20.6 (12.2)
CRP (mg/L) 12.3 (17.0) 18.0 (18.3) 0.002 16.0 (18.1)
HLA-B27-positive 129/156 (82.7%) 204/257 (79.4%) 0.409 333/413 (80.6%)
Presence of (bridging) syndesmophytes 74/109 (67.9%) 107/197 (54.3%) 0.021 181/306 (59.2%)
Start anti-TNF-α treatment 1/154 (0.6%) 256/262 (97.7%) <0.001 257/416 (61.8%)
BASDAI (0–10 3.3 (2.3) 6.1 (1.7) <0.001 5.1 (2.3)
BASFI (0–10 3.6 (2.7) 5.6 (2.2) <0.001 4.9 (2.6)
Patient GDA (0–10) 3.4 (2.7) 6.7 (1.9) <0.001 5.5 (2.7)
Physician GDA (0–10) 2.0 (1.6) 4.7 (2.2) <0.001 3.8 (2.4)
ASDAS-CRP 2.5 (1.1) 3.8 (0.8) <0.001 3.3 (1.1)
ASQoL (0–18) 5.8 (4.7) 10.0 (4.1) <0.001 8.7 (4.7)
Attrition ASQoL (≥2 missing final measures) 42 (26.1%) 57 (21.6%) 0.288 99 (23.3%)
Attrition ASDAS-CRP (≥2 missing final measures) 62 (28.5%) 56 (21.2%) <0.001 118 (27.8%)
Values represent mean (SD) or number (%).
*Number of patients per group, unless otherwise stated due to missing values.
anti-TNF-α treatment, antitumour necrosis factor α treatment; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score—C reactive 
protein; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing 
Spondylitis Functional Index; BMI, body mass index; CRP, C reactive protein; GDA, Global Disease Activity Score; GLAS, Groningen 
Leeuwarden Ankylosing Spondylitis; HLA-B27, Human Leucocyte Antigen B27; OASIS, Outcome in Ankylosing Spondylitis International 
Study.
disease activity over time, the distinct trajectories are 
denoted: (t1) Low impact of axSpA on a patient: stable 
low and acceptable ASQoL (values ranged from 0.8 to 
1.6 and stable ASDAS-CRP inactive to low disease activity 
(range 1.2 to 1.7); (t2) Moderate impact: stable moderate 
but acceptable ASQoL (range 4.5–5.6 and stable 
ASDAS-CRP high disease activity (range 2.3–2.8); (t3) 
High impact with major improvement: initial unacceptable 
ASQoL (point estimate 8.9) and ASDAS-CRP very high 
disease activity (point estimate 3.9), but major improve-
ment in both (range 1.6–2.2 for ASQoL and 1.6–1.9 for 
ASDAS-CRP); (t4) High impact with some improvement: a 
minor improvement from unacceptable average ASQoL 
(point estimate 11.0) towards a lower but still unaccept-
able state (range 8.1–9.4), in combination with a clini-
cally important improvement from ASDAS-CRP very high 
disease activity (point estimate 3.7) towards ASDAS-CRP 
high disease activity (range 2.1–2.6); (t5) Very high impact: 
persistently high and unacceptable ASQoL (range 12.6–
14.4 with ASDAS-CRP very high disease activity (range 
3.2–4.1). The estimated average trajectory lines of these 
five distinct developmental joint latent classes of ASQoL 
and ASDAS-CRP over the five time points are depicted 
in figure 1. For all trajectory-groups, HRQoL and disease 
activity mirrored to a great extent the temporal patterns 
of one another.
Characteristics of the trajectory groups
Baseline characteristics of patients in each latent class 
are shown in table 2. The trajectory of low impact of 
disease (t1) showed the largest proportion of males and 
HLA-B27 carriers, the lowest proportion of patients with 
(bridging) syndesmophytes and lowest proportion of 
patients prescribed anti-TNF-α treatment at baseline. 
In comparison to the low impact group, the moderate 
impact group (t2) is represented by a lower proportion 
of HLA-B27 carriers and a higher proportion of patients 
with (bridging) syndesmophytes. In the trajectory high 
impact with major improvement (t3), younger patients 
were found, having also the shortest symptom duration. 
Further, this group had the largest proportion of patients 
prescribed anti-TNF-α treatment. The trajectory high 
impact with some improvement (t4) had the highest propor-
tion of (bridging) syndesmophytes as well as the longest 
symptom duration. Last, the trajectory very high impact of 
disease (t5) was represented by the highest proportion 
of females. In t4 and t5, similarly as in t3, a relative high 
proportion of patients was prescribed anti-TNF-α treat-
ment at baseline, but without reaching the same effect in 
ASDAS-CRP and ASQoL.
Overall, marked heterogeneity of disease impact on 
progression of HRQoL and disease activity was observed, 
which could be linked to both individual patients’ 
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Figure 1 Joint trajectory latent classes of ASQoL–ASDAS-CRP. At the top: spaghetti plots of observed ASQoL and ASDAS-
CRP values for each individual over a period of 8 years (five measurements), coloured according to their final latent class 
assignment. Note that each class is represented by both an ASQoL and an ASDAS-CRP trajectory. At the bottom: estimated 
average trajectories’ lines with corresponding 95% confidence bands and baseline prevalence. ASDAS-CRP, Ankylosing 
Spondylitis Disease Activity Score—C reactive protein; ASQoL, Ankylosing Spondylitis Quality of Life.
characteristics and treatment with TNF-α-inhibitors. 
In this respect, a complex picture emerged. Males with 
low CRP values, HLA-B27 positivity without (bridging) 
syndesmophytes, displayed favourable clinical manifesta-
tions, despite absence of TNF-α-inhibitors. At the same 
time, effectiveness of TNF-α-inhibitors on disease impact 
was observed, particularly in younger, male patients with 
shorter symptom duration. By contrast, older females 
with longer symptom duration were more prone to a 
disadvantageous clinical picture, showing only minor or 
no treatment responsiveness.
In both cohorts, and subsequently in each revealed 
trajectory group, losses to follow-up occurred. Disease 
impact appeared to be of no influence to dropout.
dIsCussIOn
The concept of HRQoL is an increasingly important 
health-related outcome, as it reveals where medical care 
can add value to patients’ lives. In axSpA, disease activity 
is the main modifiable factor contributing to HRQoL. 
While it is recognised that HRQoL and disease activity 
vary largely within as well as across patients, there is insuf-
ficient knowledge on how their temporal codependencies 
unfold. By means of bivariate GBTM, we were able to 
explore the development of HRQoL and disease activity 
simultaneously. In this study, five trajectories of HRQoL 
and disease activity joint evolution with different impact 
of disease have been identified: two trajectories with 
stable low/moderate impact (t1 and t2), two trajectories 
with relatively stable high/very high impact (t4 and t5) 
and one trajectory with major improvement in HRQoL 
and disease activity reaching low impact of disease (t3). 
These developmental trajectories provide several substan-
tive insights: first, HRQoL and disease activity seem to 
move in parallel, as the ranking of both the HRQoL- and 
disease activity trajectories as well as their patterns of 
changes over time are to a great extent a reflection of 
each other; second, each group shows a relatively stable 
course of both HRQoL and disease activity, except for 
t4 and t3; third, the findings indicate that some patients 
may share similar perceived disease activity, but can still 
differ in the self-reported QoL (see t2 and t4 from time 
point 1 onwards, figure 1) and finally, each group shows 
some unique patient characteristics that may underlie 
the distinctiveness of their temporal courses.
The five revealed disease impact trajectories and their 
characterisations are largely consistent with the reported 
disease activity trajectories by Moltó et al.17 For example, 
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Table 2 Baseline characteristics of patients within each HRQoL—disease activity trajectory
Characteristics
Trajectory 1
Low impact
(n=55)*
Trajectory 2
Moderate 
impact
(n=105)*
Trajectory 3
High impact 
with major 
improvement
(n=86)*
Trajectory 4
High impact 
with some 
improvement
(n=124)*
Trajectory 5
Very high 
impact
(n=55)* P values
Patients from OASIS 40 (72.7%) 62 (59.0%) 4 (2.5%) 37 (29.8%) 18 (32.7%) <0.001
Patients from GLAS 15 (27.3%) 43 (41.0%) 82 (95.3%) 87 (70.2%) 37 (67.3%) <0.001
ASDAS-CRP 1.6 (0.7) 2.8 (0.8) 4.0 (0.7) 3.7 (0.8) 4.1 (0.7) <0.001
ASQoL (0–18) 1.6 (2.0) 5.4 (2.7) 9.0 (3.5) 11.1 (2.8) 14.6 (2.4) <0.001
Attrition ASQoL (≥2 
missing final measures)
16 (29.1%) 17 (16.2%) 17 (19.8%) 32 (25.8%) 17 (30.9%) 0.146
Attrition ASDAS-
CRP (≥2 missing final 
measures)
20 (36.4%) 26 (24.8%) 17 (19.8%) 36 (29.0%) 19 (34.5%) 0.158
Age (years) 43.9 (12.4) 46.0 (12.7) 40.9 (10.7) 47.9 (11.3) 45.1 (13.7) 0.001
Male sex 46 (83.6%) 71 (67.6%) 62 (72.1%) 83 (66.9%) 29 (52.7%) 0.012
Smoking—yes 16/42 (38.1%) 23/85 (27.1%) 26/74 (35.1%) 44/98 (44.9%) 20/46 (43.5%) 0.129
BMI 25.5 (3.7) 26.6 (4.9) 25.9 (3.9) 26.8 (4.3) 27.7 (5.4) 0.210
Symptom duration 
(years)
20.3 (10.9) 21.4 (12.1) 17.0 (10.9) 22.2 (13.1) 21.3 (12.6) 0.043
CRP (mg/L) 7.1 (6.9) 9.9 (9.8) 21.8 (18.9) 18.5 (21.5) 21.1 (21.1) <0.001
HLA-B27-positive 50/54 (92.6%) 73/103 (70.9%) 72/82 (87.8%) 94/119 (79.0%) 44/55 (80.0%) 0.007
Presence of (bridging) 
syndesmophytes
16/39 (41.0%) 45/73 (61.6%) 38/70 (54.3%) 64/90 (71.1%) 18/34 (52.9%) 0.017
Start anti-TNF-α 
treatment
15/54 (27.8%) 41/101 (40.6%) 81/86 (94.2%) 85/120 (70.8%) 35/55 (63.6%) <0.001
BASDAI (0–10) 1.7 (1.3) 4.0 (2.0) 6.0 (1.4) 5.9 (1.6) 7.3 (1.5) <0.001
BASFI (0–10) 1.8 (1.8) 3.8 (2.3) 5.2 (2.1) 6.1 (1.8) 7.0 (1.9) <0.001
Patient GDA (0–10) 1.8 (1.7) 4.3 (2.4) 6.9 (1.9) 6.3 (2.0) 7.3 (1.7) <0.001
Physician GDA (0–10) 2.1 (2.0) 2.8 (1.9) 4.5 (2.2) 4.4 (2.3) 4.6 (2.3) <0.001
Values represent mean (SD) or number (%).
*Number of patients per group at baseline.
anti-TNF-α treatment, antitumour necrosis factor α treatment; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score—C reactive 
protein; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing 
Spondylitis Functional Index; BMI, body mass index; CRP, C reactive protein; GDA, Global Disease Activity Score; GLAS, Groningen 
Leeuwarden Ankylosing Spondylitis; HLA-B27, Human Leucocyte Antigen B27; HRQoL, health-related quality of life; OASIS, Outcome in 
Ankylosing Spondylitis International Study.
the largest proportion of females, highest BASDAI-scores 
and BASFI-scores can be found in the trajectory very 
high impact (t5)/persistently very high disease activity. 
Conversely, younger patients in combination with 
prescription of TNF-α-inhibitors characterise the trajec-
tory high impact with major improvement (t3)/changing 
disease activity. Although our study can be seen as both 
a confirmation of and a complement to the findings by 
Moltó et al, there are some important methodological 
differences. Moltó et al have analysed patients with early 
axSpA over 3 years, while in the present study, the majority 
of the patients had established (radiographic) axSpA 
and were followed up to 8 years, thereby expanding the 
knowledge on differences in disease-behaviour in those 
with longstanding disease. Given the similarities between 
our trajectories and the ones found by Moltó et al, it 
seems that the trajectories for patients with early disease 
continue in patients with established disease. More-
over, because of the longer follow-up period, we could 
also demonstrate that most disease activity trajectories 
remained, at the group level, stable over time. Only when 
treatment with TNF-α-inhibitors was initiated in patients 
with high disease activity, a (major) improvement in 
impact of disease was seen in most patients, after which 
the values stabilised again. Last, while Moltó evaluated 
the temporal course of disease activity only, we were able 
to capitalise on its coevolution with HRQoL, demon-
strating, for the first time, the tight equivalence of their 
temporal unfolding.
For the GBTM analyses, data from two different 
cohorts, OASIS (2000–2008) and GLAS (2004–2012) 
were merged. Their timelines did not fully coincide, but 
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both were followed biennially for up to 8 years. In the 
class-comparisons, the cohorts’ distribution emerged as 
significantly different among the latent trajectories. For 
example, t3 almost entirely existed of GLAS patients, 
while t1 is largely represented by OASIS patients. This 
quasicomplete separation hints at the presence of a 
cohort effect, that is, that the GBTM model clustered 
subjects based on their shared timeline. If so, identified 
clusters would likely represent an artefact explained by 
the impact of the groups bonded by distinct periods, 
and their common environments (exposures). This 
conclusion is plausible not because of an unknown 
period effect. The impact of the cohorts’ composition 
on class-extraction, we argue, is primarily attributable 
to confounding by inclusion criteria, which happened 
to be linked to the period. OASIS patients had an estab-
lished diagnosis of axSpA at a time that biologicals were 
not yet prescribed (except for one patient included in a 
clinical trial). Conversely, nearly all GLAS patients were 
prescribed TNF-α-inhibitors because of active disease. 
Hence, the culprit underlying the differential cohort 
distribution can be pinpointed: their baseline clinical 
features, for example, disease duration, inflammatory 
components and associated treatment status. These 
factors are indisputably linked to the two outcomes. By 
means of example, the major improvement trajectory t3 
was composed of young subjects with shorter disease 
duration, high level of inflammation markers and pres-
ence of biological. However, findings also raise the possi-
bility of alternative explanations for data segmentation 
beyond the cohort effect. For instance, in one-third of 
the patients assigned to the very high impact trajectory t5 
were OASIS members, who happen to display a similar 
clinical progression as their GLAS counterparts. Like-
wise, both cohorts were well represented in trajectory 
t2. More importantly, OASIS and GLAS did not differ 
in some features that emerged as discriminatory among 
the latent classes. Therefore, a cohort effect alone does 
not seem to fully account for the identified temporal 
patterns. An interplay of mechanisms underpinning the 
level and unfolding (eg, responsiveness to treatment) of 
the developmental paths is bound to offer a biologically 
more sound explanation for the findings.
Our study has several limitations. First, temporal 
precedence cannot be established with this design as 
both outcomes were measured simultaneously, that is, it 
cannot be concluded that disease activity changed before 
HRQoL or vice versa. Second, the extracted classes and 
their names are no true entities, but only features of the 
data, since each patient was assigned to one of the groups 
with a certain probability. We provided the names to help 
describe the trajectories in terms that would enhance 
a meaningful framework for clinicians and improve 
interpretability.
The main strengths of our study are the replication of 
findings of Moltó et al, the expansion of these findings by 
using an innovative methodology allowing evaluation of 
patterns of joint evolution of HRQoL and disease activity, 
and the opportunity to better clarify the role of anti-TNFα 
treatment on the impact of the disease. The main advan-
tage of this bivariate model is that we could examine how 
these two variables simultaneously changed over time. 
The combination is expected to be more informative, 
besides being more attuned to clinicians’ demands of a 
more rounded clinical picture.
Our study has also several clinical implications. Our 
starting hypothesis was that the heterogenic clinical 
picture of axSpA might be further explored by assigning 
individuals to subgroups based on more than one param-
eter, and thereby improve diagnostic utility and clinical 
relevance of the identified data-driven classes. Patients 
in t1 showed an enduring low impact of disease with 
favourable HRQoL and low disease activity. This suggests 
that potentially, these patients may be followed-up with 
longer intervals between clinical visits. Similarly, patients 
in t3, which showed major improvement after initiation 
of anti-TNF-α treatment, with subsequently comparable 
low disease impact, can be followed-up with longer inter-
vals. However, this needs to be demonstrated in separate 
studies. More burdensome are the patients with persistent 
high disease impact, despite anti-TNF-α treatment in 
some. Possibly, concomitant fibromyalgia plays a role in 
perceived disease activity and HRQoL. Previous studies 
showed that concomitant fibromyalgia may be present in 
approximately 20% of patients with axSpA, which is asso-
ciated with poorer response to anti-TNF-α treatment.30 31 
In our study, unfortunately no information was collected 
on a history of fibromyalgia. Nevertheless, it seems that 
this population would benefit from additional support 
for their impact of disease.
In conclusion, the five latent trajectory groups revealed 
the heterogeneous character of axSpA, the joint-evolu-
tion of HRQoL and disease activity, the different expe-
riences of impact of axSpA among patients’ subgroups, 
and the characteristics of these subgroups. The evolu-
tion of HRQoL and disease activity patterns of change/
stability are tightly linked, providing supportive evidence 
to a treat-to-target strategy envisaging improvement 
of patients’ HRQoL through management of disease 
activity.
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